Yang Ze-Jun, Wang Tian-Tian, Wang Bo-Ya, Gao Han, He Cheng-Wei, Shang Hong-Wei, Lu Xin, Wang Ying, Xu Jing-Dong
Clinical Medicine of "5+3"program, School of Basic Medical Science, Capital Medical University, Beijing, China.
Department of Cardiology, Beijing An Zhen Hospital, Capital Medical University, Beijing, China.
J Inflamm (Lond). 2022 Oct 4;19(1):14. doi: 10.1186/s12950-022-00311-0.
With the incidence of hypertension increasing worldwide, more and more the mechanisms of hypertension from the perspective of immunity have found. Intestinal microbiota as well as its metabolites relationship with hypertension has attracted great attention from both clinicians and investigators. However, the associations of hypertension with lesions of a large number of immune factors including IL-17, MCP-1, IL-6, TGF-β, IL-10 and others have not been fully characterized. In this review, after introducing the immune factors as the most potent anti/pro-hypertension agents known, we provide detailed descriptions of the IL-17 involved in the pathology of hypertension, pointing out the underlying mechanisms and suggesting the clinical indications.
随着全球高血压发病率的上升,越来越多从免疫角度出发的高血压发病机制被发现。肠道微生物群及其代谢产物与高血压的关系已引起临床医生和研究人员的极大关注。然而,高血压与包括白细胞介素-17(IL-17)、单核细胞趋化蛋白-1(MCP-1)、白细胞介素-6(IL-6)、转化生长因子-β(TGF-β)、白细胞介素-10(IL-10)等在内的大量免疫因子损伤之间的关联尚未完全明确。在本综述中,在介绍了作为已知最有效的抗高血压/促高血压因子的免疫因子后,我们详细描述了参与高血压病理过程的IL-17,指出其潜在机制并提出临床指征。